Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Non-cash Items (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Non-cash Items for 3 consecutive years, with $4.8 million as the latest value for Q3 2025.

  • Quarterly Non-cash Items rose 166.46% to $4.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $4.8 million through Sep 2025, up 166.46% year-over-year, with the annual reading at $2.1 million for FY2024, 73.86% down from the prior year.
  • Non-cash Items for Q3 2025 was $4.8 million at Mereo BioPharma, down from $7.0 million in the prior quarter.
  • The five-year high for Non-cash Items was $19.0 million in Q2 2024, with the low at $1.8 million in Q3 2024.
  • Average Non-cash Items over 3 years is $8.6 million, with a median of $7.0 million recorded in 2025.
  • The sharpest move saw Non-cash Items tumbled 73.86% in 2024, then soared 166.46% in 2025.
  • Over 3 years, Non-cash Items stood at $8.1 million in 2023, then crashed by 73.86% to $2.1 million in 2024, then skyrocketed by 127.93% to $4.8 million in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $4.8 million, $7.0 million, and $2.1 million for Q3 2025, Q1 2025, and Q4 2024 respectively.